The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.
Investigators using droplet digital PCR methods are following cell-free tumor DNA in the blood, looking for patterns coinciding with immunotherapy treatment outcomes.
The foundation announced 17 junior physician scientists receiving 2017 Clinical Scientist Development awards, including several researchers conducting omics-related projects.
Scientists from The Wellcome Trust Sanger Institute, Public Health England, and elsewhere sequenced the genomes of 209 MRSA isolates collected in Europe from 1960 to 1989.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
Scientists from The Wellcome Trust Sanger Institute, Public Health England, and elsewhere sequenced the genomes of 209 MRSA isolates collected in Europe from 1960 to 1989.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.
That goal is within reach. And in this paper, we’ll show you how. By reading this white paper, you will learn:
· Why quality control is so challenging for NGS labs
· How reference materials may be the key to quality control
· The 9 key characteristics of sufficient NGS reference materials
· How to use QC metrics to monitor the health of your NGS assays
What’s been holding back more widespread adoption of liquid biopsy testing?
Lack of adequate circulating tumor DNA reference materials for developing and measuring safe, accurate and reproducible assays has been a challenge for clinical labs
Liquid biopsies are poised to revolutionize cancer diagnosis and therapy, but until now, advances in diagnostic technology - particularly at the low end of the sample input and sensitivity spectrum - have been hampered by the lack of ability of labs to reproducibly measure and assess the assay’s performance.
